Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics, Inc. filings document the regulatory disclosures of a Nasdaq-listed, clinical-stage biotechnology company developing GeneTAC® small-molecule therapies for serious degenerative genetic diseases. Its 8-K reports furnish financial results, corporate presentations, pipeline updates, and material governance events tied to board appointments, resignations, committee assignments, director compensation, and indemnification arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, stockholder voting procedures, and board structure. The filing record also identifies the company’s common stock registration on The Nasdaq Global Select Market, emerging growth company status, and public-company disclosure framework for operations, capital structure, governance, and risk reporting.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen report beneficial ownership of common stock of Design Therapeutics, Inc. As of the close of business on June 30, 2026, they report beneficial ownership of 2,366,453 shares of common stock, representing 3.8% of the class. They report no sole voting or dispositive power and shared voting and dispositive power over 2,366,453 shares, held through an investment fund managed by Point72 Asset Management. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, and Mr. Cohen controls both entities. They state ownership of 5 percent or less of the class, and note that the reporting persons should not be construed as beneficial owners for certain legal purposes.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 5,963,936 shares of Design Therapeutics, Inc. common stock, including 510,200 shares issuable upon exercise of call options. This represents 9.5% of the common stock, based on 62,456,974 shares outstanding as of April 23, 2026. The shares are held by investment funds managed by Sirenia, with Sirenia and Silverstein sharing voting and dispositive power. SILV Fund, Ltd. has the right to receive dividends or sale proceeds from more than 5% of the outstanding common stock. The reporting persons disclaim admission of beneficial owner status for Section 13 purposes and have entered into a Joint Filing Agreement.
Design Therapeutics is a clinical-stage biotech developing GeneTAC small-molecule therapies for repeat expansion diseases. For the quarter ended June 30, 2026, it reported a net loss of $20.2 million, or $0.32 per share, on operating expenses of $22.2 million. Cash, cash equivalents and investment securities totaled $207.4 million, and management expects this to fund operations for more than 12 months.
Lead FA candidate DT‑216P2 showed dose‑dependent FXN biomarker increases and clinical improvements in the RESTORE‑FA Phase 1/2 trial, with whole‑blood FXN mRNA up 65% at 1 mpk and favorable tolerability. The company plans a 12‑week 1 mpk cohort with potential extension, targeting a registrational strategy update in late 2026 and 12‑week data in early 2027. Additional GeneTAC programs include DT‑168 eye drops for FECD (Phase 2 biomarker trial, data expected 2027), DT‑818 for DM1 (Phase 1 MAD ongoing, data expected 2027), and preclinical candidates for Huntington’s disease.
Design Therapeutics reported second quarter 2026 results and pipeline updates. In the RESTORE-FA trial of DT-216P2 for Friedreich ataxia, four-week data showed dose-dependent increases in endogenous frataxin and clinical improvements. The study is being modified to treat 10 patients for 12 weeks at a planned go-forward dose of 1 mpk, designate endogenous blood FXN protein percent change from baseline as the primary efficacy endpoint, and explore a dose above 1 mpk. An update on registrational plans is expected in the fourth quarter of 2026, with 12-week data expected in the first quarter of 2027.
Across the GeneTAC® pipeline, patient dosing has begun in a Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1, with data anticipated in 2027, and a Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy is ongoing, with data now expected in 2027 following a supply delay. For the quarter ended June 30, 2026, research and development expenses were $16.4 million, general and administrative expenses were $5.8 million, and net loss was $20.2 million, or $0.32 per share. Cash, cash equivalents and investment securities totaled $207.4 million, which the company stated provides a “strong financial runway.”
Design Therapeutics director and 10% owner George Simeon received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. They vest in equal monthly installments over 12 months after June 9, 2026, or will be fully vested by the company’s next annual stockholder meeting.
Design Therapeutics, Inc. director John P. Schmid received a grant of stock options covering 30,000 shares of common stock. These options have an exercise price of $10.55 per share and expire on June 8, 2036.
The options vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. After this grant, Schmid holds options on 30,000 shares directly.
Design Therapeutics, Inc. director Rodney W. Lappe received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036.
According to the disclosure, these options were awarded as compensation and will vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the company’s next annual stockholder meeting. Following this grant, Lappe holds derivative securities representing 30,000 underlying shares directly.
Design Therapeutics, Inc. reported that director Justin D. Gover received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. The award vests in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. Following this grant, Gover holds 30,000 stock options directly.
Design Therapeutics, Inc. director David Shapiro received a stock option grant covering 30,000 shares of common stock. The option has an exercise price of $10.55 per share and expires on June 8, 2036. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. This is a compensation-related award, not an open-market purchase or sale.
Design Therapeutics, Inc. director Heather A. Berger received a grant of stock options covering 30,000 shares of Common Stock at an exercise price of $10.55 per share. These options now represent 30,000 derivative securities held directly after the transaction.
The options vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders, aligning vesting with ongoing board service.